Introduction {#Sec1}
============

Traditional laser photocoagulation has been used to treat different retinal diseases for many years \[[@CR1]--[@CR5]\]. Here, the endpoint is a visible whitening of the retina due to thermal damage of the retinal pigment epithelium (RPE) and the inner retina. However, apart from the favored therapeutic effect, the treatment can lead to undesirable side effects like visual field defects, epiretinal fibrosis, and choroidal neovascularization (CNV) in the area of the laser scar \[[@CR6]--[@CR10]\]. The mechanisms which are responsible for the therapeutic effect are still poorly understood.

Scarring seems not to be necessary to achieve a therapeutic effect. It might be the stimulation of the RPE alone and not the destroying of the photoreceptors that is needed to reach a therapeutic effect of laser photocoagulation \[[@CR11]\]. The laser energy stimulates the RPE, which leads to repair of the inner blood retinal barrier \[[@CR12]\]. A modification of the gene expression initiated by the wound healing response after laser photocoagulation could be responsible for the beneficial effect of laser photocoagulation. Sublethally injured RPE cells induce an up- and downregulation of various factors \[pigment epithelium-derived factor (PEDF), vascular endothelial growth factor (VEGF) inhibitors, VEGF inducers, permeability factors, etc.\] which restores the pathologic imbalance. RPE cells destroyed by thermal heat are not capable of inducing this biologic activity \[[@CR13], [@CR14]\]. Inagaki et al. \[[@CR15]\] showed that sublethal photothermal stimulation with a micropulse laser induces heat shock protein expression in RPE cells without cellular damage in a model of human RPE.

In subthreshold micropulse laser (SML), diffusion of heat to surrounding tissues is minimized and thereby scarring is prevented.

The neural retina can be spared by applying the minimum laser irradiance (watts per square meter) needed to raise the temperature of the RPE, but without exceeding the protein denaturation threshold. This leads to the required activation of the RPE cells, but the thermal wave will only reach the neural retina at temperatures beneath the protein denaturation threshold. Since the RPE and the neural retina are close together, the laser pulse has to be in the microsecond range and not in the millisecond range like the traditionally used supra threshold laser. For safety reasons it is not possible to deliver the required energy in one short enough laser pulse. A single laser pulse would require so much energy that there would be a high risk of bubble formation and micro-explosions, accompanied by retinal hemorrhages \[[@CR16]\]. Those side effects can be avoided by using a repetitive series of very short pulses with low energy instead of a continuous-wave laser pulse \[[@CR17]--[@CR19]\].

The micropulse operating mode and terminology were described by Dorin \[[@CR20]\]. In the traditional continuous-wave mode, a single laser pulse of 0.1--0.5 s delivers the preset laser energy. In the micropulse mode, a train of repetitive short laser pulses delivers the laser energy within an "envelope" whose width is typically 0.1--0.5s. The normal length of each pulse is 100--300 μs. The "envelope" includes "ON" time, which is the duration of each micropulse, and "OFF" time, which is the time between the micropulses. The "OFF" time is important since here the originated heat can cool down. The sum of the "ON" and "OFF" times is the period *T* and its reciprocal 1/*T* is the frequency (pulses per second) *f* in hertz (Hz). The duty cycle in percent is the ratio between "ON" time and the period*T*.

Different Lasers Available with Micropulse Mode {#Sec2}
===============================================

810-nm Diode Laser {#Sec3}
------------------

The commercially available diode lasers emit at a wavelength of 810 nm, which is in the near-infrared range of the spectrum. A feature of the 810-nm wavelength is its deep penetration into the choroid, but it is not clear if this characteristic is relevant in micropulse treatment. For all indications requiring a treatment near the foveal avascular zone, the 810-nm laser has the advantage that the laser energy will relatively spare the inner neurosensory retina and affect mainly the deeper layers \[[@CR21]--[@CR24]\]. The deep penetration is a possible benefit especially for central serous chorioretinopathy (CSC) since the choroid may play a role in the pathogenesis of CSC. A potential disadvantage of the 810-nm laser is a possible sensation of pain during treatment with a diode laser \[[@CR24], [@CR25]\], although this is a rare problem in the micropulse mode.

577-nm Yellow Laser {#Sec4}
-------------------

Another laser type which is available for micropulse treatment is the 577-nm yellow laser. The yellow laser has the advantage that xanthophyll, the pigment which is located in the inner and outer plexiform layers of the macula, absorbs the yellow light only minimally so treatment near the fovea is relatively safe \[[@CR26]\].

Applications for Subthreshold Micropulse Lasers {#Sec5}
===============================================

In this article we will review the applications for micropulse laser in macular diseases, namely CSC, diabetic macular edema (DME), and retinal vein occlusion (RVO). We will give an overview of the available literature and outline the current evidence for micropulse laser treatment in each field.

The literature search was performed in English language in the PubMed database. We used pairings of the terms "micropulse", "laser", "subthreshold", and "central serous chorioretinopathy", "chorioretinopathy", "central serous retinopathy", or "diabetic macular edema", "macular edema" and "retinal vein occlusion", "branch retinal vein occlusion", "central retinal vein occlusion". Additionally, the references of the resultant articles were checked for publications missing in the primary search. Until February 2017 we found 18 articles \[[@CR27]--[@CR44]\] concerning micropulse laser in CSC; no articles were excluded and all articles are listed in Table [1](#Tab1){ref-type="table"}. As a result of the high number of publications related to DME and micropulse treatment, we only listed the 11 prospective studies \[[@CR45]--[@CR55]\] in Table [2](#Tab2){ref-type="table"}. We found four studies \[[@CR56]--[@CR59]\] investigating micropulse laser for RVO, which are all listed in Table [3](#Tab3){ref-type="table"}.Table 1Overview of the studies investigating subthreshold micropulse laser treatment for central serous chorioretinopathyAuthorsYearEyesDisease durationLaser type and parametersStudy designRicci et al. \[[@CR27]\]20041 eyeChronic, ≥6 monthsIris Medical Oculight SLx\
810 nm, Ø not shown, 10% DC, 0.5 s, power: 500 mWCase report, SML after ICG injectionRicci et al. \[[@CR28]\]20087 eyesChronic, ≥6 monthsIris Medical Oculight SLx\
810 nm, Ø 112.5 µm, 10% DC, 0.5 s, power: 500 mWProspective, interventional, non-comparative case series, SML after ICG injectionChen et al. \[[@CR29]\]200826 eyes\
Group 1: Source leakage without RPE atrophy, *n* = 6\
Group 2: Source leakage with RPE atrophy, *n* = 9\
Group 3: Diffuse RPE decompensation with indeterminate source leakage, *n* = 11Chronic, \>4 monthsIris Medical Oculight SLx\
810 nm, Ø 125 µm, 15% DC, 0.2 s, power: titrationProspective, non-comparative, interventional case seriesLanzetta et al. \[[@CR30]\]200824 eyesChronic, \>3 monthsIris Medical Oculight SLx\
810 nm, Ø 200 µm, 15% DC, 0.2 s, power: 1000--2000 mW, mean 1350 mWProspective, interventional, non-comparative case seriesGupta et al. \[[@CR31]\]20095 eyesChronic, ≥4 weeksIris Medical Oculight SLx\
810 nm, Ø 125 µm, 15% DC, 0.2 s, power: titrationRetrospective, non-comparative, case seriesKoss et al. \[[@CR32]\]201152 eyes\
SML: *n* = 16\
BCZ: *n* = 10\
Observation: *n* = 26Chronic, \>3 monthsIris Medical Oculight SLx\
810 nm, Ø 125 µm, 15% DC, 0.2 s, power: titrationProspective, comparative, nonrandomized interventional case seriesRoisman et al. \[[@CR33]\]201315 eyes\
SML: *n* = 10\
SHAM: *n* = 5Chronic, \>6 monthsOpto FastPulse\
810 nm, Ø 125 µm, 15% DC, 0.3 s, power: 1.2× thresholdProspective, randomized, double-blind, sham-controlled pilot trial, cross over after 3 monthsMalik et al. \[[@CR34]\]201511 eyesChronic, \>3 monthsIris Medical Oculight SLx\
810 nm, Ø not shown, 5% DC, 0.2--0.3 s, power: 750--1000 mWRetrospective, interventional, non-comparative case seriesKretz et al. \[[@CR35]\]201562 eyes\
SML: *n* = 20\
HdPDT: *n* = 24\
Observation: *n* = 18Chronic, \>3 monthsIris Medical Oculight SLx\
810 nm, Ø 75--125 µm, 15% DC, 0.3 s, power: average 1500 mWProspective, randomized, interventional, comparative trialElhamid \[[@CR36]\]201515 eyesChronic, \>3 monthsIridex IQ577\
577 nm, Ø 200 µm, 10% DC, 0.2 s, power: titrationProspective, interventional, non-comparative clinical studyScholz et al. \[[@CR37]\]201538 eyesChronic, \>6 weeksQuantel Medical\
Supra Scan\
577 nm, Ø 160 µm, 5% DC, 0.2 s, power: 50% of thresholdRetrospective, non-comparative case seriesKim et al. \[[@CR38]\]201510 eyesChronic, \>6 monthsQuantel Medical\
Supra Scan\
577 nm, Ø 100 µm, 15% DC, 0.2 s, power: 50% of thresholdRetrospective, non-comparative case seriesGawęcki \[[@CR39]\]20151 eyeChronic, (disease duration not defined)Model not mentioned\
577 nm, Ø 160 µm, 5% DC, 0.2 s, power: 550 mWRetrospective case reportYadav et al. \[[@CR40]\]201515 eyesChronic, \>3 monthsQuantel Medical\
Supra Scan\
577 nm, Ø 100 µm, 10% DC, 0.2 s, power: 50% of thresholdRetrospective, non-comparative case seriesBreukink et al. \[[@CR41]\]201659 eyes\
(All eyes received HdPDT, 10 eyes with persistent SRF after up to 2 HdPDT sessions received SML)Chronic, (disease duration not defined)Iris Medical Oculight SLx\
810 nm, Ø 125 µm, 5% DC, 0.2 s, power: ≤1800 mWProspective, interventional non-comparative, case seriesÖzmert et al. \[[@CR42]\]201633 eyes\
SML: *n* = 15\
HfPDT: *n* = 18Chronic, \>6 monthsQuantel Medical\
Supra Scan\
577 nm, Ø 160 µm, 5% DC, 0.2 s, power: titrationRetrospective, comparative case seriesAmbiya et al. \[[@CR43]\]201610 eyes≥3 months without signs of RPE atrophy or diffuse leakageNavilas\
577 nm, Ø 100 µm, 5% DC, 0.1 s, power: 30% of thresholdProspective, interventional noncomparative, case seriesScholz et al. \[[@CR44]\]2016100 eyes\
SML: *n* = 42\
HdPDT: *n* = 58Chronic, ≥6 weeksQuantel Medical\
Supra Scan\
577 nm, Ø 160 µm, 5% DC, 0.2 s, power: 50% of thresholdRetrospective, comparative, interventional case seriesAuthorsFUTreatment responseCentral retinal thicknessBest corrected visual acuitySafetyLaser sessionsRicci et al. \[[@CR27]\]8 weeks1 week: SRF was reduced (1/1)Not shownBL: 0.3 logMAR\
1 week: 0.0 logMAR\
8 weeks: −0.1 logMARNo signs of laser treatment were visible on FA18 weeks: Complete resolution (1/1)Ricci et al. \[[@CR28]\]Minimum 12 monthsResponse\*: 2 weeks: 7/7 (100%)\
8 weeks: 7/7 (100%)\
Complete\*: 5/7 (71%)\
\*12 months: no recurrence in patients with complete resolution of SRF. No worsening of SRF in patients with incomplete recoveryNot shown2 weeks: all patients showed improvement\
12 months: no worsening of the BCVA\
Change: +0.19 logMAR\
Significant increase of BCVA after 12 months (*p* \< 0.05)No laser lesions were visible via funduscopic examination and on FA1Chen et al. \[[@CR29]\]Minimum 6 months (9.5 ± 2.6 months)FFU response:\
Group 1: 6/6 (100%)\
Group 2: 8/9 (89%)\
Group 3: 5/11(46%)\
All eyes: 19/26 (73%)Group 1:\
BL: 339 ± 67 µm\
FFU: 136 ± 26 µm\
Group 2:\
BL: 342 ± 84 µm\
FFU: 139 ± 34 µm\
Group 3:\
BL: 340 ± 121 µm\
FFU: 192 ± 103 µm\
Significant CRT decrease in all patients (*p* \< 0.001)Group 1:\
BL: 0.18 ± 0.08 logMAR\
FFU: 0.00 ± 0.00 logMAR\
Group 2:\
BL: 0.38 ± 0.19 logMAR\
FFU: 0.07 ± 0.06 logMAR\
Group 3:\
BL: 0.41 ± 0.28 logMAR\
FFU: 0.24 ± 0.22 logMAR\
Significant BCVA increase in all patients (*p* = 0.01)No patients developed laser-related scotoma1--3FFU complete:\
Group 1: 6/6 (100%)\
Group 2: 8/9 (89%)\
Group 3: 5/11 (46%)\
All eyes: 19/26 (73%)Lanzetta et al. \[[@CR30]\]3--36 months (mean 14 months)Response:\
1 month: 16/24 (67%)\
FFU: 18/24 (75%)BL: 328 µm\
(range 162--720 µm)\
1 month: 197 µm\
(range 93--403 µm)\
FFU: 168 µm\
(range 107--340 µm)\
Significant CRT decrease at 1 month (*p* = 0.0003) and FFU (*p* \< 0.0001)BL: 20/32 Snellen\
1 month: 20/25 Snellen\
FFU: 20/25 Snellen\
No significant increase in BCVA at 1 month (*p* = 0.64) or FFU (*p* = 0.062)−5/24 eyes showed RPE changes at the site of SML spots\
No complications1--5Complete:\
1 month: 9/24 (38%)\
FFU: 17/24 (71%)Gupta et al. \[[@CR31]\]Minimum 6 monthsFU response: 5/5 (100%)Not shownImprovement in BCVA in all patientsNo complications mentioned1--2FU complete: 4/5 (80%)Koss et al. \[[@CR32]\]10 monthsFU response: not shown\
FU complete: not shown\
Leakage activity in FA 10 months:\
SML: 2/16 (12.5%)\
BCZ: 6/10 (60%)\
Observation: 24/26 (92%)\
SML leads to significantly more leakage activity reduction than BCT (*p* = 0.0239) and observation (*p* = 0.0054)SML:\
BL: 419 ± 59 µm\
6 weeks: 387 ± 94 µm\
6 months: 329 ± 69 µm\
10 months: 325 ± 93 µm\
BCZ:\
BL: 393 ± 84 µm\
6 weeks: 355 ± 114 µm\
6 months: 334 ± 59 µm\
10 months: 355 ± 73 µm\
Observation:\
BL: 388 ± 59 µm\
6 weeks: 396 ± 57 µm\
6 months: 388 ± 63 µm\
10 months: 415 ± 53 µm\
Significant decrease in CRT at (*p* = 0.0098) but not after BCZ or observationSML:\
BL: 45.4 ± 7.2 ETDRS\
6 weeks: 47.8 ± 6.8 ETDRS\
6 months: 50.5 ± 7.3 ETDRS\
10 months: 51.6 ± 7.0 ETDRS\
BCZ:\
BL: 44.1 ± 10.8 ETDRS\
6 weeks: 41.9 ± 11.3 ETDRS\
6 months: 42.4 ± 13.6 ETDRS\
10 months: 43.5 ± 14.5 ETDRS\
Observation:\
BL: 46.4 ± 6.1 ETDRS\
6 weeks: 46.3 ± 6.9 ETDRS\
6 months: 44.9 ± 5.1 ETDRS\
10 months: 44.3 ± 5.2 ETDRS\
SML better than BCZ (*p* = 0.000047) and observation (*p* = 0.0054) at 10 monthsNo ocular adverse events, i.e., intraocular inflammation, bleeding, or IOP rise, were observed1--3Roisman et al. \[[@CR33]\]Minimum 6 monthsNot shownSML:\
BL: 420 ± 112 µm\
1 month: 307 ± 55 µm\
3 months: 265 ± 98 µm\
SHAM:\
BL: 350 ± 61 µm\
1 month: 351 ± 94 µm\
3 months: 290 ± 78 µm\
No significant decrease in CRT at 3 months after SML (*p* = 0.091) or SHAM treatment (*p* = 0.225)SML:\
BL: 35.4 ± 11.6 ETDRS\
1 month: 44.4 ± 8.1 ETDRS\
3 months: 47.9 ± 8.0 ETDRS\
SHAM\
BL: 26.6 ± 6.8 ETDRS\
1 month: 26.8 ± 7.6 ETDRS\
3 months: 25.6 ± 8.9 ETDRS\
Significant BCVA increase at 3 months after SML (*p* = 0.008) but not after SHAM treatment (*p* = 0.498)No laser scars observed at funduscopic examination or on FA1--2Malik et al. \[[@CR34]\]Minimum 2 months\
(2--12 months)FU response: 8/11 (72%)\
FU complete: not shownBL: 414 ± 137 µm\
FFU: 316 ± 97 µm\
Significant CRT decrease after SML (*p* = 0.0046)BL: 39.2 ± 15.1 ETDRS\
FFU: 45.5 ± 12 ETDRSNo evidence of RPE damage in FAF or in FA1--2Kretz et al. \[[@CR35]\]4 months4-month response (reduction of leakage activity):\
SML: 12/20 (60%)\
HdPDT: 16/24 (67%)\
Observation: 7/18 (38%)\
Significant reduction of leakage activity in both treatment groups compared to the control groupChange BL/4 months:\
SML: −69.7 µm\
HdPDT: −109.8 µm\
Observation: −89 µmChange BL/4 months:\
SML: +6.7 ETDRS\
HdPDT: +8.5 ETDRS\
Observation: +1.5 ETDRSNo evidence of secondary RPE damage in FAF after both treatments1--3Elhamid \[[@CR36]\]6 monthsResponse:\
3 months: 15/15 (100%)BL: 390 ± 46 µm\
6 months: 264 ± 24 µm\
Significant CRT decrease after SML (*p* \< 0.05)BL: 0.67 ± 0.10 Snellen\
6 months: 0.85 ± 0.10 Snellen\
Significant BCVA increase after SML (*p* \< 0.05)No sign of laser-induced lesions1--2Complete:\
3 months: 11/15 (73%)\
6 months: 13/15 (86%)Scholz et al. \[[@CR37]\]Minimum 6 weeks\
(mean\
5 ± 3 months)Response:\
6 weeks: 24/38 (63%)\
3 months: 20/23 (87%)\
6 months: 11/14 (79%)\
FFU: 28/38 (74%)BL: 402 ± 139 µm\
6 weeks: 309 ± 86 µm\
FFU: 287 ± 75 µm\
Significant CRT decrease after SML (*p* \< 0.001)BL: 0.36 ± 0.24 logMAR\
6 weeks: 0.33 ± 0.24 logMAR\
FFU: 0.30 ± 0.25 logMAR\
Significant BCVA increase after SML (*p* = 0.039)No laser burns were detected with any imaging modality1--3Complete:\
6 weeks: 5/38 (13%)\
3 months: 7/23 (30%)\
6 months: 2/14 (14%)\
FFU: 9/38 (24%)Kim et al. \[[@CR38]\]Minimum 3 monthsThere were 2 patients who had recurrent CSC. One at 6 months, one at 10 months. One patient had persistent SRF for 3 months despite total of 4 laser sessionsBL: 349 ± 53 μm\
3 months: 251 ± 29 μm\
FFU: 261 ± 38 μm\
Significant CRT decrease at 3 months (*p* = 0.009) and FFU (*p* = 0.009)BL: 0.21 ± 0.21 logMAR\
3 months: 0.06 ± 0.09 logMAR\
FFU: 0.04 ± 0.06 logMAR\
Significant BCVA increase at 3 months (*p* = 0.020) and FFU (p = 0.012)No laser scar was detected in color fundus photographs, SDOCT, or near-infrared images1--5Gawęcki \[[@CR39]\]Not specifiedResponse: 0/1After 1st treatment: no change\
After 2nd treatment: "significant amount\
of SRF present in the macular area"BL: 0.63 decimal\
FU 1st\*: no change\
FU 2nd\*: 0.32 decimal treatment\*FAF showed hyperfluorescent punctate areas referring to multispot SML pattern2Complete: 0/1Yadav et al. \[[@CR40]\]Minimum 4 weeks\
(4--19 weeks)FU:\
Response: 15/15 (100%)\
Complete: 6/15 (40%)CRT not shown\
SRF (high):\
BL: 232 µm\
FU: 49 µm\
Significant decrease in SRF (*p* \< 0.001)Change: 1 line\
BL: 20/40 Snellen\
FU: 20/30 Snellen\
Significant BCVA increase (*p* = 0.015)No evidence of RPE or retinal damage on SDOCT, FA, or on FAF1Breukink et al. \[[@CR41]\]8--118 weeksAfter mean 8.7 weeks, (range: 4--18 weeks)\
Complete after:\
1st HdPDT: 37/59 (63%)\
2nd HdPDT: 7/19 (37%)\
1st SML: 1/10 (10%)Not shownBL (all): 0.28 logMAR\
FFU (all): 0.16 logMAR\
No difference in eyes after HdPDT or SML1--2 HdPDT\
1 SMLÖzmert et al. \[[@CR42]\]Minimum 12 monthsSML:\
Response: 13/15 (87%)\
Complete: 12/15 (80%)\
HfPDT:\
Response: 14/18 (78%)\
Complete: 13/18 (72%)SML:\
BL: 287.3 ± 126 µm\
12 months: 138.0 ± 40 µm\
HfPDT:\
BL: 242.8 ± 80 µm\
12 months: 156.9 ± 60 µm\
Significant CRT decrease after SML (*p* = 0.003), but not after hfPDT *(p* = 0.098)SML:\
BL: 67.3 ± 14.2 ETDRS\
12 months: 71.5 ± 21.4 ETDRS\
HfPDT:\
BL: 60.7 ± 16.3 ETDRS\
12 months: 64.4 ± 24.9 ETDRS\
No significant increase in both groups\
SML: *p* = 0.285,\
hfPDT: *p* = 0.440No visible retinal scarring1--2Ambiya et al. \[[@CR43]\]6 monthsResponse:\
1 month: 10/10\
Complete:\
1 month: 4/10 (40%)\
3 month: 6/10 (60%)\
6 months: 6/10 (60%)BL: 298 ± 129 µm\
1 month: 200 ± 72 µm\
3 months: 179 ± 53 µm\
6 months: 215 ± 90 µm\
Significant CRT decrease at 6 months (*p* = 0.03)BL: 73.3 ± 16.1 ETDRS\
1 month: 73.1 ± 16.3 ETDRS\
3 months: 75.8 ± 14.0 ETDRS\
6 month: 76.9 ± 13.0 ETDRS\
No significant increase in BCVA (*p* = 0.59)No evidence of laser spots via funduscopic examination, on SDOCT, and on FAF\
No complications1--2Scholz et al. \[[@CR44]\]6 weeksSML 6 weeks:\
Response: 33/42 (79%)\
Complete: 15/42 (36%)\
HdPDT 6 weeks:\
Response: 34/58 (59%)\
Complete: 12/58 (21%)\
SML showed higher treatment response\
than HdPDT (*p* = 0.036)SML:\
BL: 445 ± 153 µm\
6 weeks: 297 ± 95 µm\
HdPDT:\
BL: 398 ± 88 µm\
6 weeks: 322 ± 93 µm\
Significant decrease in both groups (SML: *p* \< 0.001, hdPDT: *p* \< 0.001) CRT decrease better after SML (*p* = 0.041)SML:\
BL: 0.39 ± 0.24 logMAR\
6 weeks: 0.31 ± 0.27 logMAR\
HdPDT:\
BL: 0.35 ± 0.24 logMAR\
6 weeks: 0.31 ± 0.24 logMAR\
Significant BCVA increase after SML (*p* = 0.003), but not after HdPDT (*p* = 0.07)No laser spots detectable by funduscopic examination or on FA1*BCVA* best corrected visual acuity, *BCZ* bevacizumab (intravitreal), *BL* baseline, *CRT* central retinal thickness, *CSC* central serous chorioretinopathy, *DC* duty cycle, *ETDRS* Early Treatment Diabetic Retinopathy Study Group letters, *FA* fluorescein angiography, *FAF* fundus autofluorescence, *FU* follow-up, *FFU* final follow-up, *HdPDT* half dose photodynamic therapy, *HfPDT* half fluence photodynamic therapy, *ICG* indocyanin green, *IOP* intraocular pressure, *logMAR* logarithm of the minimum angle of resolution, *OCT* optical coherence tomography, *RPE* retinal pigment epithelium, *SDOCT* spectral domain OCT, *SML* subthreshold micropulse laser, *SRF* subretinal fluid, *Ø* spot size Table 2Overview of the studies investigating subthreshold micropulse laser treatment for diabetic macular edemaAuthorsYearEyesInclusion criteriaLaser type and parametersStudy designFazel et al. \[[@CR45]\]201668 eyes\
SML: *n* = 34\
CL: *n* = 34DME\*\
CRT \<450 µm\
Without PDR\
Without previous IVT or any retinal laserQuantel Medical\
810 nm, Ø 50--100 µm, 0.1 s, power: adjusted\
Quantel Medical\
810 nm, Ø 75--125 µm,\
15% DC, 0.0003 s, power: 2× thresholdProspective, single-blind, randomized clinical trialInagaki et al. \[[@CR46]\]201553 eyes\
810 nm: *n* = 24\
577 nm: *n* = 29DME\*, type II\
with or without NPDR/PDR\
No IVT or laser within the last 3 months\
Patients with isolated local FA dye were excludedIris Medical IQ577\
577 nm, Ø 200 µm\
15% DC, 0.2 s, power: 2× threshold, (mean 204 mW)\
Iris Medical\
OcuLight SLX, 810 nm, Ø 200 µm\
15% DC, 0.2 s, power: 2× threshold, (mean 955 mW)Prospective,\
non-randomized, interventional case series\
Additional micro-aneurysm closure in both groups at BLVujosevic et al. \[[@CR47]\]201553 eyes\
810 nm: *n* = 27\
577 nm: *n* = 26DME\* \<400 µm, type I/II diabetes\
No macular therapy, IVT, laser, ppV previouslyIris Medical IQ577\
577 nm, Ø 100 µm, 5% DC, 0.2 s, power: 250 mW, HD treatment\
Iris Medical\
OcuLight SLX,\
810 nm, Ø 125 µm, 5% DC, 0.2 s, power: 750 mW, HD treatmentProspective, masked, randomized, comparative pilot studyOthman et al. \[[@CR48]\]2014220 eyes\
Group 1 Primary treatment (*n* = 187)\
Group 2 Secondary treatment (*n* = 33)DME\* without PDR and foveal ischemia\
Group 1 without prior treatment, BCVA at least 20/80\
Group 2 with prior CL, BCVA at least 20/200Iris Medical\
OcuLight SLX 810 nm, Ø 75--125 µm, 15% DC, 0.3 s, power: 650--1000 mW confluentProspective, single-center, nonrandomized, interventional case seriesVenkatesh et al. \[[@CR49]\]201146 eyes\
SML: *n* = 23\
CL: *n* = 23DME\* without PDR\
No prior medical or laser treatment within the last 6 monthsIris Medical\
OcuLight SLX, 810 nm, Ø 125 µm, 10% DC, 2 s, power: 80--130 mW\
Zeiss Visulas\
Nd:YAG LC\
532 nm, Ø 50--100 µm, 0.1 s, power: 90--180 mWProspective, randomized interventional studyLavinsky et al. \[[@CR50]\]2011123 eyes\
ND-SLM: *n* = 39\
HD-SLM: *n* = 42\
CL: *n* = 42DME\* with CRT ≥250 µm\
No prior macular laser or IVT for DME\
No panretinal laser within last 4 monthsOpto FastPulse\
810 nm, Ø 125 µm, 15% DC, 0.3 s\
0.3 s, power: 1.2× threshold\
ND-SML: 2 invisible burn widths apart\
HD-SML: Confluent invisible burn\
Iridex, Nd:YAG LC\
532 nm, Ø 75 µm, 0.05--0.1 s, power: titration mETDRS gridProspective, randomized, controlled, double-masked clinical trialOhkoshi and Yamaguchi \[[@CR51]\]201043 eyesDME\* with CRT ≤600 µm without PDR\
Type II\
Patients with isolated local FA dye were excluded\
No prior medical or laser treatment within last 6 monthsIris Medical\
OcuLight SLX\
810 nm, Ø 200 µm, 15% DC, 0.2--0.3 s, power: 520--100 mW confluentProspective, nonrandomized interventional studyNakamura et al. \[[@CR52]\]201028 eyesDME\*\
No prior laser or surgical therapy within last 6 monthsIris Medical\
OcuLight SLX\
810 nm, Ø 200 µm, 15% DC, 0.2 s, power: titrated,\
grid pattern was usedProspectiveVujosevic et al. \[[@CR53]\]201062 eyes\
SML: *n* = 32\
CL: *n* = 30DME\*, type II\
No prior medical/laser/surgical treatment within last 6 monthsCoherent Novus Omni laser, 514 nm, Ø 100 µm, 0.1 s, power: 80--100mW mETDRS grid CL\
Iris Medical\
OcuLight SLX\
810 nm, Ø 125 µm\
5% DC, 0.2 s, power: 750mWProspective, randomized clinical trial\
(retreatment after 3 months if: CMT ≥250 µm or CMT reduction ≤50% or BCVA decrease \>5 ETDRS letters)Figueira et al. \[[@CR54]\]200984 eyes\
SML: *n* = 44\
CL: *n* = 40Both eyes DME\*, type II, \<80 years without PDR\
No prior laser treatmentIridex Oculite GLx argon green\
514 nm, Ø 100--200 µm\
0.1 s, power: titration\
Iris Medical\
OcuLight SLX 810 nm, Ø 125 µm\
15% DC, 0.3 s, power: titrationProspective, randomized, controlled, double-masked trialLaursen et al. \[[@CR55]\]200423 eyes\
SML: *n* = 12\
(Diffuse, *n* = 6; focal: *n* = 6)\
CL *n* = 11\
(Diffuse, *n* = 6; focal, *n* = 5)DME\* without PDR\
Without prior LC\
Without retinal surgeryIris Medical\
OcuLight SLX 810 nm, Ø 125 µm\
5% DC, 0.1 s, power: titration\
Novus 200 argon green\
514 nm, Ø 100 µm, 0.1 s, power: titrationProspective, randomizedAuthorsFU (months)Central retinal thicknessBest corrected visual acuitySafetyAdditional treatmentsFazel et al. \[[@CR45]\]4810 nm SML:\
BL: 373 ± 56 µm\
4 months: 344 ± 60 µm\
810 nm CL:\
BL: 355 ± 53 µm\
4 months: 350 ± 54 µm\
SML superior to CL (*p* = 0.001; 4 months)810 nm SML:\
BL: 0.59 ± 0.3 logMAR\
4 months: 0.52 ± 0.3 logMAR\
810 nm CL:\
BL: 0.58 ± 0.3 logMAR\
4 months: 0.60 ± 0.3 logMAR\
SML superior to CL (*p* = 0.015; 4 months)No laser scars after SML\
Laser scars after CLNot mentionedInagaki et al. \[[@CR46]\]12810 nm:\
BL: 488 ± 176 µm\
3 month: 404.5 µm\
6 months: 394.4 µm\
12 months: 361.8 µm\
577 nm:\
BL: 417 ± 113 µm\
3 months: 345.8 µm\
6 months: 340.6 µm\
12 months: 335.2 µm\
No significant difference between groups after 12 months810 nm:\
BL: 0.59 ± 0.41 logMAR\
3 months: 0.57 logMAR\
6 months: 0.53 logMAR\
12 months: 0.54 logMAR\
577 nm:\
BL: 0.31 ± 0.31 logMAR\
3 months: 0.32 logMAR\
6 months: 0.32 logMAR\
12 months: 0.28 logMAR\
BCVA stable in both groups, intergroup differences were not evaluatedNo laser scars in either group810 nm: 12.5% Re-SML,\
4.2% IVT\
(bevacizumab)\
5--577 nm: 3.4% Re-SMLVujosevic et al. \[[@CR47]\]6810 nm:\
BL: 340 ± 36 µm\
6 months: 335 ± 55 µm\
577 nm:\
BL: 358 ± 46 µm\
6 months: 340 ± 56 µm\
Significant decrease for 577 nm group at 6 months (*p* = 0.009) and not for 810 nm (*p* = 0.45)\
No significant difference between the groups at 6 months810 nm:\
BL: 78.6 ± 7.5 ETDRS\
3 months: 79.3 ± 6.8 ETDRS\
6 months: 77.3 ± 8.2 ETDRS\
577 nm:\
BL: 79.7 ± 6.1 ETDRS\
3 months: 79.4 ± 7.6 ETDRS\
6 months: 78.7 ± 7.4 ETDRS\
No significant difference of BCVA between groups at 3 months (*p* = 0.3) and at 6 months (*p* = 0.62)No laser scars or visible secondary effects of laser spots in either group810 nm: 85.2% Re-SML\
5--577 nm: 88.5% Re-SMLOthman et al. \[[@CR48]\]12810 nm: Primary treatment (1)\
BL: 353 ± 80 µm\
4 months: 257 ± 51 µm\
12 months: 215 ± 27 µm\
810 nm: Secondary treatment (2)\
BL: 429 ± 69 µm\
4 months: 356 ± 64 µm\
12 months: 263 ± 59 µm\
In both groups, CRT decrease was significant at 4 and 12 months (*p* \< 0.05)810 nm: primary treatment (1)\
BL: 0.21 logMAR\
4 months: 0.15 logMAR\
12 months: 0.18 logMAR\
810 nm: secondary treatment (2)\
BL: 0.50 logMAR\
4 months: 0.44 logMAR\
12 months: 0.46 logMAR\
In group 1, *BCVA* improved at 4 months (*p* = 0.017) and was stable at 12 months for 85% of the eyes\
In group 2, no significant BCVA change was observedLaser marks seen as pigmentary changes were noted 3.3% via funduscopic examination and 5.7% via FAGroup 1:\
23% Re-SML (median 2 × SML)\
11.7% IVT\
(triamcinolone)\
3.2% ppV\
Group 2:\
33% IVT\
(triamcinolone)Venkatesh et al. \[[@CR49]\]6810 nm SML:\
BL: 299 ± 50 µm\
3 months: 287 ± 53 µm\
6 months: 275 ± 63 µm\
532 nm YAG CL:\
BL: 313 ± 47 µm\
3 months: 296 ± 34 µm\
6 months: 287 ± 33 µm\
No difference between SML and CL (*p* = 0.064)810 nm SML:\
BL: 0.41 ± 0.3 logMAR\
3 months: 0.41 ± 0.3 logMAR\
6 months: 0.43 ± 0.3 logMAR\
532 nm YAG CL:\
BL: 0.33 ± 0.2 logMAR\
3 months: 0.36 ± 0.2 logMAR\
6 months: 0.41 ± 0.3 logMAR\
No difference between SML and CL (*p* = 0.77) for BCVA. Better preservation of retinal sensitivity in SML groupIn mfERG:\
810 nm SML: 4/23 eyes with focal void regions\
532 nm YAG-CL: 18/23 eyes with focal void regionsNot mentionedLavinsky et al. \[[@CR50]\]12810 nm ND-SML:\
BL: 379 (279--619) µm\
3 months: 332 (223--610) µm\
6 months: 316 (215--627) µm\
12 months: 311 (207--599) µm\
810 nm HD-SML:\
BL: 371 (297--879) µm\
3 months: 301 (203--698)µm\
6 months: 291 (201--577) µm\
12 months: 226 (187--513) µm\
532 nm YAG mETDRS CL:\
BL: 370 (269-710) µm\
3 months: 306 (209--512) µm\
6 months: 290 (208--501) µm\
12 months: 249 (199--475) µm\
HD-SML, CL were superior to ND-SLM group (*p* \< 0.001)\
No difference between HD-SDM and CL groups (*p* = 0.75)810 nm ND-SML:\
BL: 0.70 (0.4--1.3) logMAR\
3 months: 0.80 (0.4--1.3) logMAR\
6 months: 0.80 (0.4--1.3) logMAR\
12 months: 0.80 (0.3--1.3) logMAR\
810 nm HD-SML:\
BL: 0.90 (0.3--1.3) logMAR\
3 months: 0.70 (0.2--1.3) logMAR\
6 months: 0.60 (0.2--1.3 logMAR\
12 months: 0.52 (0.2--1.3) logMAR\
532 nm YAG mETDRS CL:\
BL: 0.80 (0.3--1.3) logMAR\
3 months: 0.75 (0.3--1.3) logMAR\
6 months: 0.70 (0.2--1.3) logMAR\
12 months: 0.65 (0.3--1.3) logMAR\
HD-SML with significant BCVA increase 12 months (*p* = 0.009),\
ND-SML and CL group: No improvementSML: No laser scars or visible laser burns after SML, although some very light laser-induced lesions could be identified\
CL: laser scars after CL810 nm ND-SML:\
21% re-SML (once)\
77% Re-SML (twice)\
810 nm HD-SML:\
38% Re-SML (once)\
13% Re-SML (twice)\
532 nm CL:\
32% Re-CL (once)\
24% Re-CL (twice)Ohkoshi and Yamaguchi \[[@CR51]\]12810 nm SML:\
BL: 342 ± 119 µm\
3 months: 301 ± 124 µm\
6 months: 292 ± 122 µm\
12 months: 290 ± 123 µm\
CRT reduction was significant at 3 months (*p* = 0.05) and stable afterwards810 nm SML:\
BL: 0.12 ± 0.2 logMAR\
3 months: 0.12 ± 0.2 logMAR\
6 months/12 months: N/A\
Stable BCVA until 12 monthsNo laser scars, no evidence of laser treatment\
After 1 year, one patient showed pigmentary changes19% re-SML (once)\
7% 1× grid CL\
2% 1× CL of microaneurysm\
2% IVT\
4% ppVNakamura et al. \[[@CR52]\]3810 nm SML, CFT changes:\
BL: 481 ± 110 µm\
3 months: 388 ± 127 µm\
Significant CFT reduction at 3 months (*p* = 0.004)810 nm SML\
BL: 0.47 ± 0.2 logMAR\
3 months: 0.40 ± 0.2 logMAR\
Significant BCVA improve at 3 months (*p* = 0.03)No laser scars, no evidence of laser treatmentNot mentionedVujosevic et al. \[[@CR53]\]12810 nm SML:\
BL: 358 ± 94 µm\
3 months: 341 ± 114 µm\
6 months: 346 ± 113 µm\
12 months: 312 ± 76 µm\
514 nm argon CL:\
BL: 378 ± 95 µm\
3 months: 338 ± 72 µm\
6 months: 327 ± 77 µm\
12 months: 310 ± 87 µm\
No significant difference between CL and SML810 nm SML:\
BL: 0.21 ± 0.30 logMAR\
3 months: 0.23 ± 0.29 logMAR\
6 months: 0.24 ± 0.32 logMAR\
12 months: 0.24 ± 0.25 logMAR\
514 nm argon CL:\
BL: 0.29 ± 0.30 logMAR\
3 months: 0.32 ± 0.33 logMAR\
6 months: 0.29 ± 0.27 logMAR\
12 months: 0.30 ± 0.30 logMAR\
No significant difference between CL and SMLSML: No signs of laser treatment via funduscopic examination and on FA\
CL: laser scars after CLNumber of treatments:\
SML: 2.03 ± 0.75\
CL: 2.10 ± 1.0Figueira et al. \[[@CR54]\]12810 nm SML:\
BL: 249 ± 59 µm\
12 months: 291 ± 104 µm\
514 nm Argon CL:\
BL: 255 ± 62 µm\
12 months: 284 ± 105 µm\
No significant differences between CL and SML (*p* = 0.81)810 nm SML:\
BL: 78.4 ± 8.1 ETDRS\
12 months: 71.8 ETDRS\
514 nm argon CL:\
BL: 78.0 ± 7.8 ETDRS\
12 months: 70.70 ETDRS\
No significant differences between CL and SML (*p* = 0.88)SML: 13.9% of the treated eyes showed laser scars\
CL: 59% of the treated eyes showed laser scarsNot mentionedLaursen et al. \[[@CR55]\]5--8Focal LC/diffuse LC\
Central retinal thickness\
810 nm SML focal LC (*n* = 6):\
BL: 275 µm\
3 months: 250 µm\
6 months: 256 µm\
810 nm SML diffuse LC: (*n* = 6)\
BL: 293 µm\
3 months: 318 µm\
6 months: 341 µm\
514 nm argon focal LC (n = 5)\
BL: 325 µm\
3 months: 338 µm\
6 months: 330 µm\
514 nm argon diffuse LC (*n* = 6):\
BL: 272 µm\
3 months: 308 µm\
6 months: 90 µm\
In all patients with focal edema CRT decrease significant (*p* = 0.02)BL BCVA cannot be extracted!\
810 nm SML focal LC (*n* = 6)\
3 months: +2.8 ETDRS\
6 months: +3.5 ETDRS\
810 nm SML diffuse LC (*n* = 6)\
3 months: −0.8 ETDRS\
6 months: −1.6 ETDRS\
514 nm Argon focal LC: (*n* = 5)\
3 months: +4.6 ETDRS\
6 m: +3.5 ETDRS\
514 nm argon diffuse LC (*n* = 6):\
3 months: −1.7 ETDRS\
6 months: +0.6 ETDRS\
No significant differences between groupsNo laser complications were observed in both groupsNot mentioned*BL* baseline, *CL* conventional laser, *CRT* central retinal thickness, *DC* duty cycle, *DME* diabetic macular edema, *ETDRS* Early Treatment Diabetic Retinopathy Study Group letters, *FA* fluorescein angiography, *FU* follow-up, *HD-SLM* high density subthreshold micropulse laser, *logMAR* logarithm of the minimum angle of resolution, *IVT* intravitreal drug therapy, *mfERG* multifocal electroretinography, *mETDRS* modified ETDRS (Early Treatment Diabetic Retinopathy Study Group) Grid, *ND-SLM* normal density subthreshold micropulse laser, *NdYAG* neodymium--yttrium--aluminum garnet laser, *PDR* proliferative diabetic retinopathy, *ppV* pars plana vitrectomy, *OCT* optical coherence tomography, *SML* subthreshold micropulse laser, *Ø* spot size\* Clinically significant DME Table 3Overview of the studies investigating subthreshold micropulse laser treatment for macular edema after branch retinal vein occlusionAuthorsYearEyesInclusion criteriaLaser type and parametersStudy designParodi et al. \[[@CR56]\]201535 eyes\
Group 1:\
SML: *n* = 18\
Group 2:\
IVT\
Bevacizumab\
(PRN after 3\
initial injections)\
*n* = 17ME to due BRVO\
CFT \> 250 µm\
Without non-perfusion ≥ 5 disc areas\
All eyes were previously treated with conventional grid laserIris Medical\
OcuLight SLX\
810 nm, Ø 125 µm, 15% DC, 0.3 s, power: titrationProspective, randomized, interventionalInagaki et al. \[[@CR57]\]201432 eyes\
Group 1:\
BCVA ≤20/40\
*n* = 15\
Group 2:\
BCVA \>20/40\
*n* = 17ME due to BRVO (ischemic/non-ischemic)\
CRT \<600 µm\
No prior macular therapy (LC, IVT etc.) within last 6 monthsIris Medical\
OcuLight SLX,\
810 nm, Ø 200 µm, 15% DC, 0.2 or 0.3 s, Power:\
750--1500 mW (90%) for 0.2 s or 360--2000 mW (60%) for 0.3 sRetrospective, single-center, nonrandomized, interventional case seriesParodi et al. \[[@CR58]\]200824 eyes\
Group 1:\
SML only *n* = 13\
Group 2:\
SML + IVT Triamcinolone *n* = 11ME due to BRVO\
CRT \>212 µm\
No prior laser treatment\
Without non-perfusion ≥5 disc areasIris Medical\
OcuLight SLX,\
810 nm\
Ø 125 µm\
15% DC, 0.3 s\
Power: titrationProspective randomized pilot clinical trialParodi et al. \[[@CR59]\]200636 eyes\
Group 1:\
SML grid\
*n* = 17\
Group 2: Krypton grid\
*n* = 19ME due to BRVO\
CRT \>210 µm\
No prior laser treatment\
Without non-perfusion ≥5 disc areasIris Medical\
OcuLight SLX 810 nm\
Ø 125 µm, 10% DC, 0.2 s, power: titration\
Novus Omni Krypton\
Ø 100 µm, 0.1 sProspective, randomized clinical trialAuthorsFU (months)Central retinal thicknessBest corrected visual acuitySafetyAdditional treatmentsParodi et al. \[[@CR56]\]12SML group (CFT):\
BL: 485.5 µm\
3 months: 472.0 µm\
6 months: 475.0 µm\
9 months: 475.0 µm\
12 months: 445.0 µm\
IVT group (CFT):\
BL: 484.2 µm\
3 months: 305.0 µm\
6 months: 266.0 µm\
9 months: 265.0 µm\
12 months: 271.0 µm\
IVT group significantly better (*p* = 0.001)SML group:\
BL: 0.92 logMAR\
3 months: 0.89 logMAR\
6 months: 0.89 logMAR\
9 months: 0.94 logMAR\
12 months: 0.99 logMAR\
IVT group:\
BL: 0.94 logMAR\
3 months: 0.88 logMAR\
6 months: 0.88 logMAR\
9 months: 0.85 logMAR\
12 months: 0.72 logMAR\
IVT group significantly better (*p* = 0.0085)No laser scarsNot mentionedInagaki et al. \[[@CR57]\]12Group 1: (BCVA ≤20/40 Snellen)\
BL: 409.3 µm\
1 month: 394.3 µm\
3 months: 371.3 µm\
6 months: 313.5 µm\
12 months: 303.5 µm\
Group 2: (BCVA \>20/40 Snellen)\
BL : 373.3 µm\
1 month: 353.5 µm\
3 months: 313.1 µm\
6 months: 294.1 µm\
12 months: 320.1 µm\
Significant CRT decrease at 3, 6,\
and 12 months for both groups. No\
significant difference between the\
groups at any time pointGroup 1: (BCVA ≤ 20/40 Snellen)\
BL: 0.59 logMAR\
1 month: 0.54 logMAR\
3 months: 0.54 logMAR\
6 months: 0.58 logMAR\
12 months: 0.51 logMAR\
Group 2: (BCVA \>20/40 Snellen)\
BL: 0.13 logMAR\
1 month: 0.09 logMAR\
3 months: 0.13 logMAR\
6 months: 0.09 logMAR\
12 months: 0.12 logMARNo laser scarsGroup 1:\
*n* = 8 (53.3%)\
Group 2:\
*n* = 3 (17.6%)Parodi et al. \[[@CR58]\]12SML only:\
BL: 429 µm\
3 months: 364 µm\
6 months: 320 µm\
9 months: 290 µm\
12 months: 278 µm\
SML + IVT (triamcinolone):\
BL: 476 µm\
3 months: 269 µm\
6 months: 276 µm\
9 months: 260 µm\
12 months: 283 µm\
Combined SML + IVT showed better response at 3 months (*p* \< 0.001). No difference between groups from 9th month onSML only:\
BL: 0.76 logMAR\
3 month: 0.78 logMAR\
6 months: 0.78 logMAR\
9 months: 0.73 logMAR\
12 months: 0.65 logMAR\
SML + IVT (triamcinolone):\
BL: 0.67 logMAR\
3 months: 0.50 logMAR\
6 months: 0.45 logMAR\
9 months: 0.36 logMAR\
12 months: 0.35 logMAR\
Combined SML + IVT showed significant better response at 9th and 12th months (*p* \< 0.009, *p* = 0.011, respectively)No Laser scarsNot mentionedParodi et al. \[[@CR59]\]24SML grid:\
BL: 480 µm\
6 months: 457 µm\
12 months: 217 µm\
18 months: 215 µm\
24 months: 208 µm\
Krypton grid:\
BL: 454 µm\
6 months: 252 µm\
12 months: 226 µm\
18 months: 229 µm\
24 months: 217 µm\
Krypton showed better response at 3 months and 6 months (*p* \< 0.001). SML showed better response from 12th month on (*p* \< 0.001)SML grid:\
BL: 0.70 logMAR\
6 months: 0.70 logMAR\
9 months: 0.55 logMAR\
12 months: 0.51 logMAR\
24 months: 0.49 logMAR\
Krypton grid:\
BL: 0.69 logMAR\
6 months: 0.60 logMAR\
9 months: 0.58 logMAR\
12 months 0.57 logMAR\
24 m: 0.56 logMAR\
No statistical difference between groupsNo laser scars after SMLNot mentioned*BRVO* branch retinal vein occlusion, *BL* baseline, *CFT* central foveal thickness, *CRT* central retinal thickness, *DC* duty cycle, *FA* fluorescein angiography, *IVT* intravitreal drug therapy, *logMAR* logarithm of the minimum angle of resolution, *ME* macular edema, *PRN* pro re nata, *SML* subthreshold micropulse laser

As a result of different study designs, uneven inclusion and exclusion criteria, different laser types, treatment parameters, and various outcome measures, a direct comparison of the studies is limited. We looked for similarities referring to the outcome measures for making comprehensive conclusions regarding the treatment outcome. In Tables [1](#Tab1){ref-type="table"}, [2](#Tab2){ref-type="table"}, and [3](#Tab3){ref-type="table"}, all studies are listed, but individual studies were excluded from the calculations as a result of missing information or prior treatment. The studies had a high variety regarding the follow-up visits. If available, after calculation of the decrease in central retinal thickness (CRT) in optical coherence tomography (OCT) in all individual studies, a weighted average value was calculated on the basis of the number of patients in each study. The best corrected visual acuity (BCVA) was not consistently presented in the different studies. To compare the BCVA, we converted all visual acuity data to Early Treatment Diabetic Retinopathy Study (ETDRS) letters equivalent using the formula ETDRS letters = 85 + 50 × log (Snellen fraction) \[[@CR60]\]. If a large enough number of studies provided information about a control group, we additionally analyzed the control group regarding CRT, BCVA, and treatment outcome.

This article was based on previously conducted studies and did not involve any new studies of human or animal subjects performed by any of the authors.

Central Serous Chorioretinopathy (CSC) {#Sec6}
======================================

In CSC a serous detachment of the neurosensory retina leads to decreased vision \[[@CR61]\]. The acute form of CSC is often self-limiting so that treatment is not always necessary. But some patients develop the chronic form of CSC with impending permanent structural damage and vision loss \[[@CR62]--[@CR64]\]. For patients with extrafoveal leakage, a continuous-wave laser photocoagulation is a treatment option. Studies showed an acceleration of subretinal fluid (SRF) resolution but no change in final visual acuity or recurrence rate after conventional laser. Furthermore, adverse events like CNV, scotomas, enlargement of the laser spot, and reduction of contrast sensitivity can occur \[[@CR3], [@CR62], [@CR65]--[@CR67]\]. Another treatment option is photodynamic therapy (PDT) which is used also in juxtafoveal or subfoveal leakage. But even with reduced treatment settings, complications like RPE atrophy, choroidal hypoperfusion, transient reduction of macular function, and CNV can occur \[[@CR68]--[@CR71]\].

Bandello et al. \[[@CR72]\] presented the first pilot study investigating SML treatment for CSC in 2003. They reported a high treatment success with complete resorption of SRF in five out of five eyes within 1 month and no recurrence of SRF during follow-up of 2--6 month after non-visible subthreshold micropulse diode laser (810 nm) treatment. No evidence of RPE or retinal changes was discernible at fluorescein angiography (FA) or fundus biomicroscopy after laser treatment.

Table [1](#Tab1){ref-type="table"} shows all identified studies investigating micropulse laser treatment for CSC. In Table [4](#Tab4){ref-type="table"}, the treatment outcome after SML, PDT, and observation for CSC is presented.Table 4Treatment outcome after SML, PDT, observation and conventional laser for CSC, DME, and BRVOTreatmentChange in CRT (µm)Change in BCVA (ETDRS letters)CSCSML−131 (range −69.7 to −204)^a^6.34 (range −15 to 20)^d^PDT−85 (range −76 to −109.8)^b^3.87 (range 2 to 8.5)^b^Observation−25 (range 26 to −89)^c^0.67 (range −2.1 to 2.5)^c^DMESML−74.9 (range −138 to 48)^e^1.26 (range −6.6 to 19)^e^Conventional laser−43.6 (range −145 to 28.7)^f^−0.29 (range −7.3 to 7.5)^f^BRVOSML−122.59 (range −272 to −40.5)^g^2.98 (range −3.5 to 9.5)^g^*CSC* central serous chorioretinopathy, *DME* diabetic macular edema, *BRVO* branch retinal vein occlusion, *BCVA* best corrected visual acuity, *CRT* central retinal thickness, *ETDRS* Early Treatment Diabetic Retinopathy Study Group letters, *PDT* photodynamic therapy, *SML* subthreshold micropulse laser^a^199 patients from 11 studies, 7 studies excluded from the calculations, one due to prior PDT treatment \[[@CR37]\], six due to absence of information about the CRT^b^100 patients from 3 studies^c^49 patients from 3 studies^d^216 patients from 14 studies, two studies excluded due to prior PDT \[[@CR37], [@CR41]\], two due to absence of information about the concrete BCVA \[[@CR28], [@CR31]\]^e^613 patients from 11 studies^e^195 patients from 7 studies^f^80 patients from 3 studies, one study excluded from the calculation due to prior conventional laser treatment \[[@CR56]\]

Treatment Response {#Sec7}
------------------

Most studies defined a treatment response as a reduction in CRT measured in spectral domain OCT (SDOCT). A complete resolution of SRF in SDOCT was defined as a complete treatment response. Two studies measured the leakage activity in FA as a parameter for treatment response \[[@CR32], [@CR35]\]. For simplicity reasons we do not distinguish between the different definitions for treatment response in our calculations. Few studies did not mention the amount of patients with treatment response. If we were able to work out the treatment response from the data shown in the paper, we quote the response; otherwise the studies were excluded from the calculations \[[@CR33], [@CR38]\]. One case report was excluded from the calculation because of prior bevacizumab treatment \[[@CR39]\], and two studies were excluded since they included patients with prior PDT \[[@CR37], [@CR41]\]. Few studies mentioned only the response or the complete response, and those studies were included in the calculations.

We included 191 patients from 12 studies for the calculations of the treatment response and 176 patients from 11 studies for the complete response. A total of 156 (79.6%) of the 191 patients showed a treatment response at the last mentioned follow-up: 112 (63.6%) of the 176 patients had a complete resolution of SRF. Only two studies showed data concerning the improvement rate in an untreated control group: a complete resolution of SRF was seen in 2 (8%) out of 26 eyes at the last follow-up and a reduction in SRF in 7 (39%) out of 18 eyes.

Four studies had a control group consisting of patients receiving PDT treatment (half dose PDT in three studies and half fluence PDT in one). The treatment response could be calculated from 100 patients in three studies and the complete treatment response from 135 patients in three studies. A total of 64 (64%) of the 100 patients responded to PDT and 62 (46%) of 135 patients showed complete response.

Safety {#Sec8}
------

The majority of studies described no visible retinal changes after the micropulse laser treatment. In six patients from two studies \[[@CR30], [@CR39]\] pigmentary changes at the level of the RPE were seen after SML but without any visual implications for the patients. Complications like scar formation, visible laser burns, or CNV did not occur.

Diabetic Macular Edema (DME) {#Sec9}
============================

DME is a frequent complication of diabetic retinopathy (DR) and the most common cause of visual impairment in patients with DR \[[@CR5]\]. Since the ETDRS trial \[[@CR1], [@CR73]\] showed that laser photocoagulation reduced the risk of moderate visual loss by 50% in eyes with clinically significant macular edema, laser photocoagulation became the standard therapy for DME for many years. Depending on the kind of edema, the treatment pattern can be selected: a focal photocoagulation for localized areas of leakage and a grid pattern for a diffuse macular edema. Continuous-wave photocoagulation comes with potential side effects like epiretinal fibrosis, CNV, and enlargement of laser scars \[[@CR7], [@CR8], [@CR74]\]. Table [3](#Tab3){ref-type="table"} shows only the prospective studies investigating micropulse laser treatment for diabetic macular edema. A total of 613 patients from 11 studies were included in the calculations. The inclusion and exclusion criteria varied between studies; some did not allow prior treatment at all, most of them only excluded patients with treatment in the prior 3--6 months. All listed studies were included in the calculations for change in CRT and BCVA. Seven studies had a control group consisting of 195 patients treated with conventional laser. The same calculations were performed for those studies.

Table [4](#Tab4){ref-type="table"} displays the treatment outcome after SML and conventional laser for DME.

Safety {#Sec10}
------

In the majority of studies no laser scars occurred after SML. Four studies reported scar formation or pigmentary changes in a small amount of eyes after SML treatment \[[@CR48], [@CR50], [@CR51], [@CR54]\]. Retinal changes were only observed in eyes treated with duty cycles of 15%; lower duty cycles did not lead to scar formation in the listed studies.

Venkatesh \[[@CR49]\] et al. reported focal void regions in multifocal electroretinogram in 4 out of 23 eyes after SML treatment with 10% duty cycle compared to 18 out of 23 eyes after conventional laser.

Macular Edema Due to Retinal Vein Occlusion (RVO) {#Sec11}
=================================================

Macular edema is a common complication of branch RVO (BRVO) \[[@CR75]\]. Grid laser photocoagulation reduces the visual acuity loss after BRVO with macular edema \[[@CR75]\]. Parodi et al. \[[@CR59]\] reported a similar outcome in visual acuity improvement and resolution of macular edema after SML treatment compared to conventional laser, but without retinal changes after SML. Table [3](#Tab3){ref-type="table"} summarizes studies investigating SML treatment for macular edema after BRVO. In total 80 patients from three studies could be included in the calculations, and one study was excluded because of prior conventional laser treatment \[[@CR56]\]. As a result of the small number of studies and the variety in control groups (bevacizumab, SML + triamcinolone, conventional laser), the control groups were not separately analyzed. Only one study \[[@CR48]\] had a control group where patients were treated with anti-VEGF agents, the current standard therapy for macular edema due to BRVO.

Table [4](#Tab4){ref-type="table"} presents the treatment outcome after SML for macular edema after BRVO.

Safety {#Sec12}
------

No study described complications like scar formation, visible laser burns, or CNV.

Problems and Challenges of SML Treatment {#Sec13}
========================================

Although the majority of the studies showed some efficacy of the SML treatment for CSC, DME, or BRVO, the treatment parameter differed significantly between the individual studies. No study compared the outcome of SML with different treatment parameters like higher or lower duty cycle. Concerning the treatment power, most authors titrated the power individually for each patient, but the path was not consistent. The titration is probably the most challenging part of the SML treatment. Since the laser surgeon did not see an effect of the treatment, there is a high risk of undertreatment and treatment failure accordingly. A solution to this problem could be to use fixed laser parameters with the same power for all patients. But so far there is not enough published data to choose the best treatment power and to evaluate the safety and the treatment success of subthreshold micropulse treatment with fixed parameters. For the future, controlled trials comparing treatment outcome and safety of individual titrated SML treatment and SML treatment with fixed parameters would be desirable. Those studies should include safety follow-up with multimodal imaging including autofluorescence, OCT, and fundus photographies as well functional follow-up with microperimetry or multifocal electroretinogram.

Conclusion {#Sec14}
==========

For CSC, the presented studies showed a higher efficacy of the micropulse laser treatment for both morphology and visual function in comparison to no treatment or PDT. The decrease in CRT was highest after SML (−131 µm), followed by PDT (−85 µm) and the no-treatment group (−25 µm). Moreover, 64% of patients showed no SRF after SML compared to 46% after PDT and 8% after observation.

No study reported any complications after up to five SML treatment sessions, so even an early treatment could be considered for potentially better results. Chen et al. \[[@CR29]\] showed that the SML treatment outcome was best in patients with source leakage without RPE atrophy. The investigated literature did not allow an evaluation of the best treatment parameter or the best laser wavelength.

Regarding the treatment of DME, the investigated studies showed efficacy also in morphology and function. The decrease in CRT and increase in BCVA after SML (−74.9 µm and +1.26 ETDRS letters) was better than after conventional laser (−43.6 µm and −0.29 ETDRS letters), but no study had a control group in which patients were treated with anti-VEGF agents. After the RISE and RIDE studies \[[@CR76]\] and the approval of ranibizumab for the treatment of DME, anti-VEGF agents became the standard treatment for DME. Without any trial, comparing SML treatment with anti-VEGF agents, we do not know when SML treatment could be an alternative first-line treatment for DME. Nevertheless, SML might be an option in patients not responding sufficiently to, or who are not able to follow an anti-VEGF therapy (e.g., high costs, compliance problems due to frequent visits for the injections and ophthalmological controls). Chen et al. \[[@CR77]\] had come to a similar result in their meta-analysis of randomized controlled trials comparing subthreshold micropulse diode laser photocoagulation and conventional laser. They reported a significantly better visual acuity and a similar decrease in CRT after SML compared to conventional laser. They underline the advantage of the SML treatment in terms of the affordability compared to the cost-intensive anti-VEGF therapy.

On the subject of macular edema after BRVO, SML treatment shows some efficacy as well. But in comparison to the current standard treatment, intravitreal anti-VEGF, SML was inferior to intravitreal bevacizumab \[[@CR56]\]. However, similar to DME, SML treatment could be an option for adjunct treatment for selected patients.

In summary, in all three indications micropulse laser is an efficacious and safe treatment option. Owing to its higher efficacy and the excellent safety profile compared to PDT, it could become the first-line therapy in CSC, potentially even in acute cases.
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